explore -WSS

explore

author：entertainment 2025-09-06 04:37:10 - browse：66

Diversity in clinical trials concept — Adobe

The persistent lack of diversity among participants in clinical trials is a critical issue that is harming both populations that have long been left out of pivotal medical studies and the entire biomedical research enterprise, according to the authors of a report released Tuesday by the National Academies of Sciences, Engineering and Medicine.

Describing the need to move away from trials that focus largely on white men as “urgent,” the report’s authors called for a paradigm shift that gives less power to institutions that fund and conduct clinical research and more to communities under study. The sternly worded report said funding to include and recruit more diverse participants should be a priority that is enforced and said such investments could eventually lead to massive cost savings as the nation’s health disparities are reduced.

“An equitable clinical research enterprise would include trials and studies that match the demographics of the disease burden under study,” the report said. “However, we remain far from achieving this goal.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Walmart eyes Medicare Advantage provider ChenMed

WSS

Vertex Pharmaceuticals may move headquarters in Boston

Food makers to regulators: Ultra

Supreme Court mifepristone arguments center on docs' right to sue

The Readout: Lenmeldy, GLP

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Study says nonprofit hospitals fall short in charity care spending

Wikipedia

explore

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

FDA's naming rule on biosimilars has undermined competition

Alkermes shareholders re

Diverse clinical trials: Why aren’t we there yet?

In Memoriam: Notable people who died in 2023

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

At least 13 dead in Texas as scorching temps continue

Merck drug for rare lung condition set for approval in U.S.

Drug repurposing or repositioning? The language matters

Eliminate the waiting period for sterilization covered by Medicaid

leisure time

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

New weight loss drugs vying to be the next Wegovy or Mounjaro

Study says nonprofit hospitals fall short in charity care spending

Diverse clinical trials: Why aren’t we there yet?

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

leisure time

explore

Wikipedia

focus